DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) –Link here Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET. Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for […]
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017 – link here DUBLIN, Ireland, Feb. 10, 2017 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2016. Recent highlights: Initiated pivotal field efficacy and safety studies of frunevetmab, the Company’s anti-nerve […]
Posted in Mobile Health Jamie Hartford on January 26, 2017 – link here The Smartinhaler system from New Zealand-based Adherium Ltd. connects with an app to monitor medication adherence, usage, and dosage. Daphne Allen The Smartinhaler system uses software to help providers gain insights about how patients use their medication. Smartinhaler, a “smart” personal medication monitoring system from Adherium Ltd., has shown effectiveness in reducing hospital […]
Northridge, CA, Perth, Australia and London, United Kingdom – 25 January 2017 – link here. Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that Adam Kelliher, Avita’s Chief Executive Officer, will be a panel member at the Biotech and Money / […]
AB-SA01 meets primary endpoints of safety and tolerability and reduces S. aureus bacterial load in all patients Business update call scheduled for January 4, 2017 at 4:30 p.m. Eastern CATEGORY: Featured Monday, December 19, 2016 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 “We are delighted with the […]
Business update call scheduled for today at 4:30 p.m. Eastern CATEGORY: Featured Wednesday, January 4, 2017 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We saw decreases in S. aureus bacterial load in all patients treated with AB-SA01 in our Phase 1 trial, which is particularly encouraging since most […]
DUBLIN, Ireland, Dec. 12, 2016 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET) today announced it has initiated a pivotal field efficacy and safety study of frunevetmab, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy which is being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in cats. Nexvet expects to report data […]
By Heather Mack December 12, 2016 – link here SHARE 66 Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile health tools can be used to manage asthma. Adherium’s Smartinhaler technology, which uses sensors to track […]
With nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company’s Smartinhaler to improve outcomes for children with poorly controlled asthma should boost the pairing of digital technologies with drugs. Download the press release here Or visit Medtech Insight
Tuesday October 25, 2016 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections in patients suffering […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: